title: A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
abstract: OBJECTIVE
  Therapy for high-grade gliomas remains unsatisfactory. Paclitaxel and topotecan have separately demonstrated activity against gliomas. We conducted a Phase II trial of these agents in combination with filgrastim (G-CSF) in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
  
  
  METHODS
  Adult patients with radiographic evidence of recurrent or progressive tumor following primary therapy were eligible for study. Patients received paclitaxel 175 mg/m2 IV over 3 h on day 1 and topotecan 1.0 mg/m2 IV over 30 min on days 1-5. Filgrastim 5 microg/kg was given days 6-14 for neutrophil support. Treatment cycles were repeated every 21 days.
  
  
  RESULTS
  Twenty patients were enrolled on study, and seventeen were considered evaluable for response. Two patients (12/%) exhibited partial remission and seven patients (41/%) exhibited stable disease in response to therapy. Hematologic toxicity was common with 25 /% of patients experiencing grade III or IV leukopenia despite G-CSF support. Two patients died of infectious complications on protocol, prompting suspension of further accrual.
  
  
  CONCLUSIONS
  Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma. The significant hematotoxicity encountered, however, cannot justify further investigation of this combination in patients with high grade brain tumors.
authors.affiliation: Neuro-Oncology Program, Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, 1 Medical Center Drive, New Hampshire, Lebanon, NH 03756, USA. j.marc.pipas@hitchcock.org
authors.forename: J Marc
authors.initials: JM
authors.lastname: Pipas
authors.forename: Louise P
authors.initials: LP
authors.lastname: Meyer
authors.forename: C Harker
authors.initials: CH
authors.lastname: Rhodes
authors.forename: Laurence D
authors.initials: LD
authors.lastname: Cromwell
authors.forename: Carol E
authors.initials: CE
authors.lastname: McDonnell
authors.forename: Linda S
authors.initials: LS
authors.lastname: Kingman
authors.forename: James R
authors.initials: JR
authors.lastname: Rigas
authors.forename: Camilo E
authors.initials: CE
authors.lastname: Fadul
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000401:mortality; D001932:Brain Neoplasms / Q000188:drug therapy*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D000069585:Filgrastim; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage; D011994:Recombinant Proteins; D013921:Thrombocytopenia / Q000139:chemically induced; D019772:Topotecan / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D019772:Topotecan; D017239:Paclitaxel; D000069585:Filgrastim
references.citation: Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):980-6
references.pmid: 12095566
references.citation: J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24
references.pmid: 7932806
references.citation: Cancer Chemother Pharmacol. 1994;34(2):171-4
references.pmid: 8194169
references.citation: Oncologist. 2003;8(1):76-82
references.pmid: 12604734
references.citation: J Clin Oncol. 1997 Sep;15(9):3121-8
references.pmid: 9294475
references.citation: J Clin Oncol. 1996 Jun;14(6):1964-5
references.pmid: 8656268
references.citation: Ann Oncol. 2001 Jul;12(7):923-7
references.pmid: 11521796
references.citation: J Clin Oncol. 2001 Apr 1;19(7):1893-900
references.pmid: 11283120
references.citation: Cancer Res. 1993 Feb 15;53(4):725-7
references.pmid: 8428353
references.citation: J Clin Oncol. 1995 Sep;13(9):2230-7
references.pmid: 7545219
references.citation: J Clin Oncol. 1990 Jul;8(7):1277-80
references.pmid: 2358840
references.citation: Cancer Chemother Pharmacol. 2001 Sep;48(3):188-96
references.pmid: 11592339
references.citation: Ann Oncol. 1996 Feb;7(2):205-7
references.pmid: 8777179
references.citation: J Natl Cancer Inst. 1992 Dec 2;84(23):1816-20
references.pmid: 1331485
references.citation: J Clin Oncol. 1998 Jun;16(6):2032-7
references.pmid: 9626200
references.citation: J Clin Oncol. 1995 Aug;13(8):2066-71
references.pmid: 7636549
references.citation: Biometrics. 1993 Sep;49(3):741-52
references.pmid: 8241370
references.citation: J Clin Oncol. 1994 Mar;12(3):539-43
references.pmid: 8120551
references.citation: J Clin Oncol. 1996 Feb;14(2):600-9
references.pmid: 8636777
references.citation: Cancer Res. 1994 Oct 1;54(19):5118-22
references.pmid: 7923128
references.citation: Drugs. 1995 Jan;49(1):11-9
references.pmid: 7705211
references.citation: Cancer. 2001 Jan 15;91(2):417-22
references.pmid: 11180089
references.citation: J Clin Oncol. 1998 Jun;16(6):2188-94
references.pmid: 9626220
references.citation: Cancer. 1993 Apr 15;71(8):2585-97
references.pmid: 8453582
references.citation: Expert Opin Pharmacother. 2001 Mar;2(3):491-505
references.pmid: 11336601
references.citation: J Clin Oncol. 1994 Oct;12(10):2013-21
references.pmid: 7931469
references.citation: Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):113-9
references.pmid: 11516860